QuidelOrtho Reports Third Quarter 2026 Financial Results, Highlights Resilience in Core Diagnostics and Launches $80 Million Cost-Saving Initiative
QuidelOrtho Corporation, a leading global provider of diagnostic solutions, has announced its financial results for the third quarter ended September 27, 2026. The company reported total revenue of $619 million, reflecting a 12% decline compared with the same period last year, both on a reported basis and in constant currency. Despite the decline, QuidelOrtho highlighted continued strength across its core laboratory diagnostics and immunohematology businesses, supported by established customer relationships, a broad global installed base and sustained demand for diagnostic testing solutions.
The third-quarter results reflect several challenges affecting the company’s performance, particularly lower sales in China, changes in in vitro diagnostics (IVD) pricing and a softer respiratory season in the United States. These factors placed pressure on overall revenue, especially within the Point of Care Diagnostics business.
However, excluding the impact of respiratory-related sales, China and the U.S. Donor Screening business, QuidelOrtho reported underlying revenue growth of 2% on a reported basis and 3% in constant currency. This performance indicates that several areas of the company’s broader diagnostics portfolio continued to demonstrate resilience despite challenging market conditions.
Alongside reporting its quarterly financial results, QuidelOrtho announced a new cost transformation and enterprise restructuring program. The initiative is intended to strengthen the company’s financial performance, improve operational efficiency and create a more focused business structure. Through the program, management expects to generate more than $80 million in annual savings during 2027.
Third-Quarter Revenue Performance Reflects Market Challenges
QuidelOrtho reported total revenue of $619 million for the third quarter of 2026, representing a 12% decrease compared with the prior-year period. The decline was primarily associated with lower sales in China, reduced respiratory testing demand and changes affecting the U.S. Donor Screening business.
The company’s Labs business generated revenue of $353 million, representing a 6% decline both as reported and in constant currency.
Lower sales in China were the primary factor affecting the Labs segment. The market has experienced changes in in vitro diagnostics pricing, creating pressure on sales performance for diagnostic manufacturers. These pricing developments have affected the company’s revenue contribution from the region.
Despite the decline in overall Labs revenue, performance outside China remained positive. Labs revenue excluding China increased 3% on a reported basis and 4% in constant currency, demonstrating continued demand across the company’s broader international and domestic markets.
The results suggest that QuidelOrtho’s laboratory diagnostics portfolio continues to benefit from its established relationships with healthcare providers, laboratories and other diagnostic customers.
The company provides a broad range of laboratory testing solutions designed to support clinical decision-making, disease detection and patient management. These products serve an important role in healthcare systems by helping medical professionals obtain diagnostic information that supports treatment decisions.
Immunohematology Business Maintains Stable Performance
QuidelOrtho’s Immunohematology business delivered relatively stable results during the third quarter.
Revenue from the segment reached $142 million, remaining flat compared with the prior-year period on a reported basis while increasing 1% in constant currency.
Outside China, the business achieved stronger performance, with revenue increasing 2% on a reported basis and 3% in constant currency.
Immunohematology solutions play an important role in transfusion medicine, blood banking and hospital laboratory operations. These diagnostic products support blood typing, compatibility testing and other procedures that help healthcare professionals determine whether donated blood products are suitable for patients.
The segment’s stable performance highlights the continued importance of these diagnostic services across healthcare systems. Hospitals and blood banks depend on reliable testing technologies to support transfusion safety and patient care.
QuidelOrtho’s established customer relationships and global installed base remain important advantages in this market. Maintaining customer confidence, supporting existing diagnostic platforms and delivering dependable testing solutions are central to sustaining the segment’s performance.
Point of Care Diagnostics Faces Softer Respiratory Testing Demand
The Point of Care business recorded the largest revenue decline among QuidelOrtho’s reported business areas during the third quarter.
Revenue reached $120 million, representing a 27% decrease compared with the same period in 2025, both on a reported basis and in constant currency.
The decline was primarily attributed to a softer respiratory season, which reduced demand for respiratory diagnostic testing.
Point of care testing allows healthcare professionals to perform diagnostic procedures close to patients rather than relying exclusively on centralized laboratories. These solutions are commonly used in hospitals, clinics, physician offices and other healthcare settings where timely test results can support faster clinical decisions.
Respiratory testing demand can fluctuate depending on seasonal disease activity, infection patterns and patient testing behavior. A weaker respiratory season can therefore have a direct impact on manufacturers with significant exposure to respiratory diagnostic products.
For QuidelOrtho, the lower demand contributed to the overall reduction in quarterly revenue and highlighted the impact of seasonal market conditions on the company’s financial performance.
The company is working to strengthen its operating structure and better align resources with the requirements of its different diagnostic markets. Its new restructuring program specifically includes a more focused Point of Care Diagnostics business.
QuidelOrtho Reports Quarterly Loss Despite Solid Core Business Performance
QuidelOrtho’s third-quarter financial results reflected the combined impact of lower revenue and ongoing operational pressures.
The company reported a GAAP net loss of $54 million for the quarter, while its GAAP operating loss reached $8 million.
The GAAP net loss margin was 8.7%, and the GAAP operating loss margin was 1.2%.
Despite the reported losses, adjusted EBITDA totaled $148 million, representing an adjusted EBITDA margin of 23.9%.
The difference between the company’s GAAP and adjusted financial measures reflects the impact of items excluded from adjusted performance calculations. These measures provide investors with additional information about the company’s underlying operating performance, although they should be considered alongside reported GAAP results.
QuidelOrtho reported GAAP diluted loss per share of $0.78. Meanwhile, adjusted diluted earnings per share were $0.31.
The company’s cash generation also remained an important area of focus. Operating cash flow was $20 million during the third quarter, while free cash flow was $0.3 million.
The limited free cash flow highlights the importance of the company’s plans to improve its cost structure, manage expenses and strengthen operational efficiency.
CEO Highlights Resilience Across Core Diagnostics Businesses
Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho, emphasized that the company’s Labs and Immunohematology businesses continued to demonstrate solid underlying performance during the third quarter.
He attributed this resilience to the strength of customer relationships and the company’s extensive global installed base.
Blaser acknowledged that challenging conditions in China and weaker respiratory testing demand continued to affect the company’s overall financial results.
He also highlighted the company’s decision to introduce a new cost transformation and enterprise restructuring program as an important step toward strengthening its business operations.
According to the CEO, the initiative is designed to improve profitability and cash flow while evolving the company’s operating model to better address the distinct needs of its customers and markets.
The restructuring will focus on increasing customer orientation, strengthening accountability for business performance and aligning technology development and investment priorities more closely with the requirements of individual business areas.
Management believes these actions will help offset near-term market pressures while creating a stronger foundation for sustainable long-term growth.
New Cost Transformation Program Targets More Than $80 Million in Annual Savings
A major announcement accompanying QuidelOrtho’s third-quarter results was the launch of its new cost transformation and enterprise restructuring program.
The initiative is intended to further improve the company’s cost structure and create a more streamlined operating model.
As part of the restructuring, QuidelOrtho plans to organize its operations around two focused businesses: Core Diagnostics and Point of Care Diagnostics.
The revised structure is designed to provide clearer business responsibilities and improve how the company manages its products, customers, technologies and investments.
By establishing more focused business units, QuidelOrtho expects to improve decision-making and create stronger alignment between its commercial strategies and customer requirements.
The company believes that the new operating model will also allow it to allocate resources more effectively across its diagnostic businesses.
One of the central objectives of the program is to improve profitability through sustainable cost reductions.
QuidelOrtho expects the initiative to deliver more than $80 million in annual savings in 2027.
The savings are expected to support improved operating performance and cash flow while providing additional flexibility for investments in the company’s diagnostic technologies and business priorities.
However, implementing the restructuring will involve certain short-term expenses.
The company expects to record approximately $30 million to $35 million in one-time restructuring charges during the fourth quarter of 2026.
These charges are associated with the implementation of the new operating model and the broader organizational changes required to achieve the targeted cost savings.
Although the restructuring expenses will affect reported financial results in the near term, management expects the longer-term financial benefits to support improved profitability.
Core Diagnostics and Point of Care Businesses to Receive Greater Strategic Focus
The decision to organize the company around Core Diagnostics and Point of Care Diagnostics represents an important change in QuidelOrtho’s operating strategy.
Both businesses serve different customer requirements and operate in markets with distinct commercial and technological needs.
Core Diagnostics includes laboratory-based testing solutions that support hospitals, clinical laboratories and other healthcare organizations. These solutions are important for routine testing, disease identification and the management of complex medical conditions.
Point of Care Diagnostics focuses on testing technologies that provide results closer to the patient. These products support faster diagnostic decision-making in a variety of healthcare environments.
By creating more focused business structures, QuidelOrtho aims to strengthen customer engagement and establish clearer accountability for financial and operational performance.
The company also expects the new structure to improve the alignment of technology development and investment decisions.
This could help the organization prioritize product development opportunities based on customer needs, market demand and the long-term growth potential of its individual business areas.
The restructuring is also intended to support a more efficient allocation of resources, allowing the company to respond more effectively to changes in diagnostic testing markets.
Global Diagnostics Market Remains an Important Growth Opportunity
QuidelOrtho operates in the global diagnostics industry, where healthcare providers increasingly depend on accurate and timely testing to support patient care.
Laboratory diagnostics, immunohematology and point of care testing each play important roles in healthcare delivery.
Hospitals and laboratories require reliable diagnostic platforms to support clinical decisions, while blood banks depend on immunohematology technologies to maintain transfusion safety.
At the same time, point of care testing continues to support healthcare professionals seeking faster access to diagnostic information.
Although market conditions can vary by geography and testing category, the company’s broad diagnostic portfolio provides exposure to several important areas of healthcare.
Its established global installed base and customer relationships remain significant strengths as it works to improve business performance.
However, pricing changes, seasonal testing patterns and competitive pressures continue to create challenges for diagnostic manufacturers.
QuidelOrtho’s latest restructuring initiative reflects the company’s efforts to adapt its operating model to these changing conditions.
QuidelOrtho Focuses on Long-Term Profitability and Sustainable Growth
The third-quarter 2026 results highlight a mixed performance for QuidelOrtho. While total revenue and GAAP earnings were affected by lower sales in China and weaker respiratory testing demand, the company continued to demonstrate underlying strength in its Labs and Immunohematology businesses.
Growth outside China and stable immunohematology performance indicate that important parts of its diagnostic portfolio remain resilient.
The company’s adjusted EBITDA of $148 million also demonstrates its ability to maintain adjusted operating earnings despite the decline in overall revenue.
At the same time, the introduction of a new cost transformation and enterprise restructuring program signals a stronger emphasis on profitability, cash generation and operational accountability.
With more than $80 million in annual savings targeted for 2027, QuidelOrtho expects the program to contribute meaningfully to its financial performance.
The transition toward two focused business units, Core Diagnostics and Point of Care Diagnostics, is intended to create a more customer-oriented organization and support better alignment of technology investments.
As the company moves forward, its priorities include managing market challenges, strengthening customer relationships, improving operational efficiency and investing in diagnostic solutions that address evolving healthcare needs.
Overall, QuidelOrtho’s third-quarter results demonstrate the challenges facing the global diagnostics business while highlighting management’s efforts to improve the company’s financial and operational foundation. Through its restructuring initiative and targeted cost reductions, the company aims to mitigate near-term pressures and establish a stronger platform for sustainable long-term growth.
Source link: https://www.quidelortho.com/
